Statin therapy in adults with type 2 diabetes reduces all-cause mortality and major cardiovascular disease risk across various baseline cardiovascular risk levels.
2
In low-risk patients with a 10-year cardiovascular risk below 10%, statin initiation showed a 0.53% ARR for mortality and 0.83% for major cardiovascular disease.
3
Higher baseline cardiovascular risk correlates with increased absolute risk reductions, reaching 4.30% for mortality and 4.57% for major CVD in high-risk patients.
4
The study utilized a target trial framework to minimize biases, with participants matched based on demographics and clinical measures over a median follow-up of 75 to 81 months.
5
Clinicians are encouraged to consider statin therapy for all adults with type 2 diabetes, even those with low short-term cardiovascular risk, due to observed benefits.
